Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
L-Ascorbic acid (HB1238)
Description:Antioxidant. Enhances iPSC generation and increases reprogramming efficiency. Supports mesenchymal stem cell proliferation.
Purity:>99%
(±)-Bay K 8644 (HB1209)
Description:L-type Ca2+ channel agonist. Aids iPSCs generation from Mouse embryonic fibroblasts.
Purity:>99%
ω-Conotoxin MVIIC (HB1219)
Description:N-, P- and Q-type voltage-dependent Ca2+ channel blocker
Purity:>99%
Mibefradil dihydrochloride (HB1226)
Description:Potent, reversible T- / L-type Ca2+ channel blocker
Purity:>95%
ω-Agatoxin IVA (HB1212)
Description:Potent, selective P-type / Q-type Ca2+ channel blocker
Purity:>95%
SNX 482 (HB1235)
Description:Reported to be a potent, selective Cav2.3 (R-type) channel blocker
Purity:>95%